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Abstract
Background: The epidermal growth factor receptor (EGFR) inhibitor, gefitinib, has been reported to successfully
treat advanced non-small cell lung cancer patients with genetic mutations in EGFR. The aim of this study was to
investigate the existence of EGFR mutations in carcinoma of esophagogastric junction, and also to explore the
possibility of treating carcinoma of esophagogastric junction using gefitinib.
Methods: From Aug. 2009 to Jun. 2010, 65 patients with carcinoma of esophagogastric junction underwent
surgical resection. The tumor tissue and corresponding blood specimens were collected from all cases. The DNA
was extracted and PCR amplification was accomplished based on designed primers for exons 18, 19, 20, and 21.
EGFR exons 18, 19, 20 and 21 of both cancer cell and white blood cell were finally successfully sequenced.
Results: In exon 20, a variant from CAG to CAA at codon 787 (2361G-> A) was identified in 19 patients, which was
a genomic variation of EGFR since it was found in both cancer tissue and white blood cells. This EGFR alteration
was a synonymous single nucleotide polymorphism (SNP) since CAA and CAG were encoding the same amino-
acid of Glutamine (Q787Q, NCBI database 162093G > A, SNP ID: rs10251977). No genetic alteration was found in
exons 18, 19 or 21.
Conclusions: Adenocarcinoma of esophagogastric junction rarely presents EGFR mutation, especially gefitinib-
associated mutations such as L858R, or delE746-A750. This means that the gefitinib-based gene target therapy
should not be recommended for treating carcinoma of esophagogastric junction.
Keywords: Epidermal growth factor receptor, Adenocarcinoma of esophagogastric junction, Gene mutation, Single
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Background
Epidermal growth factor receptor (EGFR) plays an impor-
tant role in the proliferation, apoptosis regulation, and
protein secretion of the cells [1]. Human EGFR gene
locates at chromosome 7p11-13 including 28 exons, which
transduces and synthesizes a 179 KD Tyrosine Kinase
(TK) family membrane protein consisting of 1186 amino
acids. EGFR is structurally composed of three parts as
extracellular ligand binding area, transmembrane (TM)
and intracellular endogenous TK activity domain. After
binding of EGFR and ligands such as EGF or TGF-a, the
intracellular TK domain is activated and subsequent
downstream biological signal transduction is stimulated
resulting in the regulation of cell proliferation [2]. EGFR
overexpression is currently discovered in some solid
tumors of lung, breast, prostate, colon, ovary, gastrointest-
inal tract, head and neck. It can be the target of cancer
therapy using small molecule inhibitors like special EGFR-
TK targeted inhibitor to treat EGFR-overexpression
tumors [3].
The EGFR-TK specific small molecule inhibitor (TKI) of
Iressa (Gefitinib) was approved by FDA (U.S Food and
Drug Administration) for advanced non-small cell lung
cancer (NSCLC) treatment in May 2003 [4]. But the appli-
cation of gefitinib suggested that just 10%-15% of the
patients presented significant response [5]. Further studies
revealed that just the tumor cell with EGFR-TK mutation
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(L858R, del742-759) could match good response to gefiti-
nib [6,7].
According to the previous researches on EGFR DNA
sequencing in Japan, South Korea and China, the inci-
dence of EGFR mutation of NSCLC in Asian population
was significantly higher than that in Europe or America.
Also it was more frequent in female or non-smoking or
adenocarcinoma patients. Recently a new EGFR mutation
of T790M was discovered that explained the resistance to
gefitinib after drug administration [8]. On the other hand,
based on the mutation mechanisms above pharmacologist
could design new inhibitors targeting EGFR mutation
locus. In esophageal squamous cell carcinoma (ESCC),
about 30.8% of the tumor cells presented EGFR overex-
pression in relation to the bad prognosis and long-term
survival. This pointed out the possibility of TKI applica-
tion in ESCC treatment. Phase I and II clinical trials of
gefitinib in ESCC treatment were being carried out [9,10].
Carcinomas of the esophagus and esophagogastric junc-
tion (EGJ) are both common malignancies in China. For
example, the annual incidence of carcinoma of EGJ was as
high as 17.25/100 000 from 1988 to 2002 in the high inci-
dence area of Ci County in northern China and currently
the incidence was still rising yearly [11,12]. It locates at
esophagogastric junction but may differ from either eso-
phageal carcinoma or gastric cancer pathologically and
clinically. Majority of the patients with dysphagia symptom
are diagnosed as advanced stage so that the surgical treat-
ment is not effective and satisfactory. It has been reported
that the resectability of carcinoma of esophagogastric
junction was 84.6% and 5-year survival rate was as low as
20.9% [13]. Therefore the postoperative adjuvant che-
motherapy is usually recommended.
No study on EGFR mutation in adenocarcinoma of eso-
phagogastric junction has been reported so far as we
known. Preliminary immunohistochemical analysis discov-
ered that more than 32% of the patients with esophagogas-
tric junction carcinoma presented EGFR overexpression,
which related with tumor stage, lymph node metastasis
and postoperative tumor-free survival.
In this study, we planned to extract DNA from cancer
tissue and corresponding peripheral blood cell from
patients with EGJ cancer, then perform DNA sequencing
of EGFR-TK domain including exons 18, 19, 20 and 21 in
order to assess the EGFR mutation in carcinoma cell initi-
ally and predict the therapeutic effect of small molecule
inhibitor of gefitinib on EGJ cancer.
Methods
From Aug. 2009 to Jun. 2010, 65 patients with carcinoma
of esophagogastric junction underwent surgery in our
department (Table 1). The cancer tissue and correspond-
ing peripheral blood specimen were obtained from these
patients and stored temporarily in -80°C freezer. There
were 61 men and 4 women. Twenty-one patients
declared the smoking history (all were men, 18 were cur-
rent smokers and 3 were ex-smokers), with the mean
smoking index of 280 cigarettes per year (range: 120-500
cigarettes per year). All the patients were diagnosed as
adenocarcinoma and had no any preoperative neoadju-
vant therapy.
DNA of the tumor tissue and white blood cells was suc-
cessfully extracted by routine proteinase K digestion and
precipitated with TIANamp Blood/cell/tissue genomic
DNA extraction kit (Tiangen, Beijing, China) according to
the manufacturer’s instruction.
In order to amplify EGFR exons 18, 19, 20 and 21 that
located in EGFR-TK domain, we designed the PCR pri-
mers by using Primer Premier 6.0 (Premier, Canada). The
designed primers were checked repeatedly and of which
the specificity were also confirmed at website of In-silico
PCR (http://genome.ucsc.edu/cgi-bin/hgPcr?command=-
start). Exon 18: Forward: 5’-CAA GTG CCG TGT CCT
GG-3’; Reverse: 5’-AAA TGC CTT TGG TCT GTG AA-
3’, Exon 19: Forward: 5’-ATA TCA GCC TTA GGT GCG
G-3’, Reverse: 5’-GGG AAA GAC ATA GAA AGT GAA
CA-3’, Exon 20: Forward: 5’-TTC ACA GCC CTG CGT
AAA C-3’, Reverse: 5’-TTG AAT CCA AAA TAA AGG
AAT GT-3’; Exon 21: Forward: 5’-TGG TCA GCA GCG
GGT TAC-3’, Reverse: 5’-TCA TTC ACT GTC CCA
GCA AG-3’. PCR amplification was carried out on ABI
9700 PCR thermal cycler (Applied Biosystems, USA) in a
20 uL reaction system containing 10 ul of SUPER Taq
Mix 2× (dNTP, Mg2+ and Buffer), 7 ul of ddH2O, 1 ul of
forward (F) primer, 1 ul of reverse (R) primer and 1 ul of
DNA template. The PCR cycling conditions consisted of
an initial denaturation step at 94°C for 2 min, followed by
35 cycles of 94°C for 20 s, 52°C for 10 s, 72°C for 30 s, and
final extension step at 72°C for 2 min. The reactions were
then held at 4°C before analysis.
The PCR products were purified with PCR product puri-
fication kit (BioDev-Tech, Beijing, China) according to
manufacturer’s instructions and sequenced directly using
the Applied Biosystems sequencer 9700 according to the
Table 1 Patients characteristics
No.
Patients 65
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manufacturer’s instruction. All sequence variants were
confirmed by sequencing the products of independent
PCR amplifications in both directions.
Results and Discussion
The DNA sequencing of exons 18, 19, 20 and 21 was
successfully performed and output with the *. ABL for-
mat file by Chromas 2.0. We analyzed all the DNA
sequences. In exon 20, a variant from CAG to CAA at
codon 787 (2361G-> A) was identified in 19 patients
(29.2%) (Figure 1), which was a genomic variation of
EGFR since it was found in both cancer tissue and
white blood cells. No other variants were discovered in
exons 18, 19, or 21. The discovered EGFR variant in
exon 20 was a synonymous mutation because CAA and
CAG were encoding the same amino-acid of Glutamine
(Q787Q). It was considered as single nucleotide poly-
morphism (SNP). This SNP has been deposited in NCBI
database (162093G > A, SNP ID: rs10251977).
The translated amino acids from DNA form the pri-
mary structure of protein. Furthermore, the steric con-
figuration of the protein is functional structure which is
preserved by molecular linkage between amino acids. If
some particular amino acid is substituted, the molecular
Figure 1 The variant from CAG to CAA at codon 787 in exon 20. The variant from CAG to CAA at codon 787 in exon 20 (arrows), which
was a genomic variation of EGFR since it was found in both cancer tissue and white blood cells, and this was a synonymous mutation because
CAA and CAG were encoding the same amino-acid of Glutamine (Q787Q).
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linkage should be changed resulting in the protein func-
tion alteration. Take L858R as example, which is a fre-
quent EGFR mutation in NSCLC where leucine (L) is
substituted by arginine (R) at the locus. The chemical
distance between these two amino acids is 102 (Gran-
tham, 1974), so the steric configuration of EGFR in this
domain would be changed and this structural alteration
facilitates the combination between TKI and EGFR-TK.
This hypothesis may explain the sensitivity to gefitinib
of the patients with EGFR L858R mutation. From this
concern, if similar mutation exists in carcinoma of eso-
phagogastric junction, the TKI therapy to carcinoma of
esophagogastric junction will be promising.
In our study, carcinoma of esophagogastric junction
rarely presents EGFR mutations, especially gefitinib-
associated mutations such as L858R and delE746-A750.
This is different from NSCLC, gastric cancer, esophageal
carcinoma, and colonic or pancreatic carcinoma. This
suggests the gefitinib-based small molecular target ther-
apy is not appropriately applied in treating EGJ cancer.
A similar result was found in study of Barrett’s adeno-
carcinoma [14]. In exons 19 and 21 of EGFR, just
K754K was found without other mutation identified. It
was concluded that mutations within the tyrosine kinase
domain of EGFR associated with sensitivity of NSCLC
patients to gefitinib were not present in Barrett’s adeno-
carcinoma. Some study revealed that the kinase domain
of EGFR was highly conserved in whole gastric cancer
cell lines and cases, therefore treatment with gefitinib
should not be recommended for such malignancy [15].
A meta-analysis showed that the incidence of EGFR
mutations in NSCLC varied according to cigarette-
smoking history [16]. The detected EGFR mutations in
exons 18, 19, and 21 of the patients with lung cancer
were 48.6% in never smokers, 33.9% in former smokers,
and 16.6% in current smokers. The mutations were less
common in people who smoked for more than 15 pack-
years or who stopped smoking cigarettes less than 15
years ago [17]. The presence of EGFR exon 19 deletions
and L858R in patients with lung adenocarcinoma were
found in 15% from former smokers, 6% from current
smokers and 52% from never smokers [18]. However,
there was little report on the correlation between smok-
ing history and EGFR mutation in gastrointestinal carci-
noma. In our study, all 65 patients with adenocarcinoma
of EGJ, of which 21 cases were current or former smo-
kers, presented none EGFR sensitive mutation. The cor-
relation between smoking history and EGFR mutation in
adenocarcinoma of EGJ was not definitely clear here
and needs further investigation.
Besides the lack of meaningful EGFR mutation, we
found that a synonymous SNP in exon 20 of EGFR
gene. SNP is the DNA sequence variation caused by the
single nucleotide alteration which exists widespread in
human genome with the frequency more than 1%. SNPs
may locate within coding sequences of genes, non-cod-
ing regions of genes, or in the intergenic regions. SNPs
within a coding sequence may not change the amino
acid sequence of the translated protein, due to degener-
acy of the genetic code. A SNP in which both forms
lead to the same polypeptide sequence is termed synon-
ymous, as is the case of Q787Q in our study.
Previous studies on EGF gene were carried out and
concluded that the SNP of EGF +61 G/A polymorphism
was associated with ESCC in a Chinese population and
the variant genotypes of GA/AA were associated with a
significantly decreased risk of ESCC compared with the
wild-type homozygote GG [19]. Other investigation sug-
gested no association between EGF gene polymorphism
and gastric cancer [20].
Choi and co-workers screened several EGFR SNPs in
lung cancer cell and five SNPs were identified including
127378C > T, 142285G > A, 162093G > A, 181946C >
T and 187114T > C. Meanwhile the SNP of 181946C >
T was found be associated with the incidence of lung
cancer [21]. So the SNP could be used as predictive
marker for the genetic susceptibility to lung cancer
according to their study. Kaneko et al reported the same
SNP discovery of Q787Q with the rate of 33% in the
esophageal squamous cell carcinoma cell, and a signifi-
cant difference was seen in the overall survival between
patients with and without the EGFR heterozygous geno-
type in their study [22]. Could this SNP of Q787Q be a
clinically useful biomarker for predicting the prognosis
of ESCC or EGJ cancer patients? It will be a promising
study and need much further research. Also more stu-
dies are warranted to identify the relationship between
this SNP change and the biological features and clinical
manifestations of EGJ cancer.
Conclusions
Adenocarcinoma of esophagogastric junction rarely pre-
sents EGFR mutation, especially gefitinib-associated
mutations such as L858R, or delE746-A750. This means
that currently the gefitinib-based gene target therapy
should not be recommended for treating the carcinoma
of esophagogastric junction.
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